Literature DB >> 32091438

Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis.

Salvatore Corrao1,2, Giuseppe Natoli1, Christiano Argano1.   

Abstract

BACKGROUND: Cholangiocarcinoma is a cancer with poor prognosis. The detection of risk factors is fundamental to identify subjects at higher risk of cholangiocarcinoma. Nonalcoholic fatty liver disease (NAFLD) represents a leading cause of chronic liver disease worldwide. Recent data suggested that NAFLD increases the risk of cholangiocarcinoma development. However, it is necessary to better explain the strength of association between NAFLD and cholangiocarcinoma.
METHODS: A systematic research of current case-control, cohort, clinical trial and meta-analysis on the main electronic databases was made. A recent systematic review was recognized. We performed cumulative meta-analyses with sensitivity analysis excluding studies with large sample size and with great clinical heterogeneity, then we checked for further studies. At the final step, three trial sequential analyses were done as well.
RESULTS: NAFLD determines an increased risk of total cholangiocarcinoma and intrahepatic cholangiocarcinoma (iCCA) development: odds ratio (OR) (95% confidence interval [CI]): 1.88 (1.25-2.83), OR (95% CI): 2.19 (1.48-3.25), respectively. On the contrary, NAFLD does not show a significant effect on extrahepatic cholangiocarcinoma (eCCA) (OR (95% CI): 1.48 (0.93-2.36). The trial sequential analyses regarding total cholangiocarcinoma and iCCA showed that z-curve was outside computed alpha boundaries, proving that the positive association was conclusive. The trial sequential analysis about eCCA showed that z-curve was inside computed futile boundaries, proving that negative results were conclusive.
CONCLUSION: The performance of new sensitive analyses and the respective trial sequential analyses, after withdraw of confounding factors, suggested the existence of definitive association only between NAFLD and iCCA development and not with eCCA.

Entities:  

Mesh:

Year:  2021        PMID: 32091438     DOI: 10.1097/MEG.0000000000001684

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

Review 1.  Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.

Authors:  Xing Chen; Jinpeng Du; Jiwei Huang; Yong Zeng; Kefei Yuan
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

Review 2.  Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.

Authors:  Fausto Petrelli; Michele Manara; Silvia Colombo; Gabriella De Santi; Michele Ghidini; Marco Mariani; Alessandro Iaculli; Emanuele Rausa; Valentina Rampulla; Marcella Arru; Matteo Viti; Veronica Lonati; Antonio Ghidini; Andrea Luciani; Antonio Facciorusso
Journal:  Neoplasia       Date:  2022-05-27       Impact factor: 6.218

Review 3.  Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.

Authors:  Eda Kaya; Yusuf Yilmaz
Journal:  J Clin Transl Hepatol       Date:  2021-10-19

Review 4.  Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics.

Authors:  Rocio I R Macias; Maria J Monte; Maria A Serrano; Jesús M González-Santiago; Isabel Martín-Arribas; André L Simão; Rui E Castro; Javier González-Gallego; José L Mauriz; Jose J G Marin
Journal:  Aging (Albany NY)       Date:  2021-10-11       Impact factor: 5.682

Review 5.  Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?

Authors:  Athanasia Mitsala; Christos Tsalikidis; Konstantinos Romanidis; Michail Pitiakoudis
Journal:  Curr Oncol       Date:  2022-06-25       Impact factor: 3.109

6.  Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.

Authors:  Milind Javle; Sunyoung Lee; Nilofer S Azad; Mitesh J Borad; Robin Kate Kelley; Smitha Sivaraman; Anna Teschemaker; Ishveen Chopra; Nora Janjan; Shreekant Parasuraman; Tanios S Bekaii-Saab
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

Review 7.  Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach.

Authors:  Felix Krenzien; Nora Nevermann; Alina Krombholz; Christian Benzing; Philipp Haber; Uli Fehrenbach; Georg Lurje; Uwe Pelzer; Johann Pratschke; Moritz Schmelzle; Wenzel Schöning
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.